Replimune Group

$Replimune Group(REPL)$ Replimune 宣布 FDA 接受 BLA 重新提交 RP1 用于治疗晚期黑色素瘤

#药闻简讯# $Replimune Group(REPL)$ - FDA 已接受晚期黑色素瘤 RP1 申请的重新提交。PDUFA 日期为 2026 年 4 月 10 日

$Replimune Group(REPL)$ 18？

$Replimune Group(REPL)$ 暴涨75%盘前。重新递交BLA。
#Seeking# #biotech# 黑色素瘤
CRL以后。

$Replimune Group(REPL)$ 承接非常强，根本跌不下去啊。

$Replimune Group(REPL)$ 看来要到明年4月份才有希望回本了今天这点幅度还不够，毕竟也是曾经单日-75%的跌幅啊

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-25-114122  Size: 5 KB 网页链接

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-25-123279  Size: 5 KB 网页链接

$Replimune Group(REPL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-25-123286  Size: 5 KB 网页链接

$Replimune Group(REPL)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001493215-25-000047  Act: 34  Size: 12 KB 网页链接

$Replimune Group(REPL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-25-107438  Act: 34  Size: 261 KB 网页链接

$Replimune Group(REPL)$ 144 Report of proposed sale of securities Accession Number: 0001968582-25-001147  Act: 33  Size: 4 KB 网页链接

10/20，Replimune$Replimune Group(REPL)$ 披露FDA已接受其溶瘤免疫疗法RP1（vusolimogene oderparepvec）的重新申请，该公司股价应声上涨逾一倍。FDA将于明年4月10日前就该申请做出决定。
自去年7月FDA以支持性试验设计和患者人群存在问题为由拒绝批准RP1以来，围绕RP1的不确定性一直存在。上...

$Replimune Group(REPL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001628280-25-049884  Act: 34  Size: 7 MB 网页链接

$Replimune Group(REPL)$ S-3/A [Amend] Registration statement under Securities Act of 1933 Accession Number: 0001104659-25-107762  Act: 33  Size: 751 KB 网页链接

$Replimune Group(REPL)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0001104659-25-112548  Act: 34  Size: 11 KB 网页链接

$Replimune Group(REPL)$ RTW Investments, LP 及 Roderick Wong 医学博士已向美国证券交易委员会提交了13G表格，披露其持有Replimune Group, Inc. 8.2%的股权。文件显示RTW Investments与黄博士共同持有6,395,732股Replimune普通股。这些股份由RTW Investments管理的基金持有，黄博士担任该公司的...

$Replimune Group(REPL)$ 144 Report of proposed sale of securities Accession Number: 0001968582-25-001182  Act: 33  Size: 4 KB 网页链接

$Replimune Group(REPL)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000080255-25-000829  Act: 34  Size: 7 KB 网页链接

$Replimune Group(REPL)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-25-100605  Act: 34  Size: 204 KB 网页链接